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Objectives: Carotid artery stenting has been proposed as an alternative to carotid endarterectomy in cerebral revascular-
ization. Although early results from several centers have been encouraging, concerns remain regarding long-term
durability of carotid artery stenting. We report the incidence, characteristics, and management of in-stent recurrent
stenosis after long-term follow-up of carotid artery stenting.
Methods: Carotid artery stenting (n  122) was performed in 118 patients between September 1996 and March 2003.
Indications included recurrent stenosis after previous carotid endarterectomy (66%), primary lesions in patients at
high-risk (29%), and previous ipsilateral cervical radiation therapy (5%). Fifty-five percent of patients had asymptomatic
stenosis; 45% had symptomatic lesions. Each patient was followed up with serial duplex ultrasound scanning. Selective
angiography and repeat intervention were performed when duplex ultrasound scans demonstrated 80% or greater in-stent
recurrent stenosis. Data were prospectively recorded, and were statistically analyzed with the Kaplan-Meier method and
log-rank test.
Results: Carotid artery stenting was performed successfully in all cases, with the WallStent or Acculink carotid stent.
Thirty-day stroke and death rate was 3.3%, attributable to retinal infarction (n  1), hemispheric stroke (n  1), and
death (n  2). Over follow-up of 1 to 74 months (mean, 18.8 months), 22 patients had in-stent recurrent stenosis
(40%-59%, n  11; 60%-79%, n  6; >80%, n  5), which occurred within 18 months of carotid artery stenting in 13
patients (60%). None of the patients with in-stent recurrent stenosis exhibited neurologic symptoms. Life table analysis
and Kaplan-Meier curves predicted cumulative in-stent recurrent stenosis 80% or greater in 6.4% of patients at 60 months.
Three of five in-stent recurrent stenoses occurred within 15 months of carotid artery stenting, and one each occurred at
20 and 47 months, respectively. Repeat angioplasty was performed once in 3 patients and three times in 1 patient, and
repeat stenting in 1 patient, without complications. One of these patients demonstrated asymptomatic internal carotid
artery occlusion 1 year after repeat intervention.
Conclusions: Carotid artery stenting can be performed with a low incidence of periprocedural complications. The
cumulative incidence of clinically significant in-stent recurrent stenosis (>80%) over 5 years is low (6.4%). In-stent
restenosis was not associated with neurologic symptoms in the 5 patients noted in this cohort. Most instances of in-stent
recurrent stenosis occur early after carotid artery stenting, and can be managed successfully with endovascular techniques.
(J Vasc Surg 2003;38:1162-9.)
Carotid artery stenting (CAS) has emerged as an alter-
native to repeat operation in the management of recurrent
stenosis after previous carotid endarterectomy (CEA).1,2
This approach has also been suggested for management of
other subgroups, including patients with significant medi-
cal comorbid conditions, anatomically inaccessible lesions
above C2, and radiation-induced stenosis.3 Endovascular
management of these high-risk subsets has been recom-
mended on the basis of acceptable immediate postproce-
dural complications, and results of short-term follow-up
from single-institution1,2 and industry-sponsored trials4
(M. H. Wholey, 2003, personal communication).
However, concerns remain regarding long-term dura-
bility of carotid artery stenting. The incidence of postpro-
cedural in-stent restenosis ranges from 1% to 50% in pub-
lished reports.5-9 The reported rate of in-stent recurrent
stenosis (ISR) depends on the definition of recurrent ste-
nosis, duration of follow-up, and methods of diagnosis and
calculation used. Most studies have had relatively short
follow-up periods (12 months),8-10 and report absolute
recurrence rates weighting each procedure equally, regard-
less of duration of follow-up. This may result in underre-
porting of ISR stenosis rates. The current study was under-
taken to prospectively determine the incidence,
characteristics, and significance of ISR after long-term fol-
low-up of carotid artery stenting. Rates of ISR to any
degree were determined with life-table analysis to more
accurately reflect recurrence relative to the population at
risk at each interval of observation.
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Patients. Carotid artery stenting (n  122) was per-
formed in 118 consecutive patients between September
1996 and March 2003 in an endovascular suite. These
procedures were performed as part of an institutional re-
view board–approved program in CAS. Patients with symp-
tomatic carotid stenosis 50% or greater and asymptomatic
carotid stenosis 80% or greater were considered for this
protocol. Eligibility was further determined on the basis of
criteria established at a consensus conference,3 including
recurrent stenosis after previous CEA; primary lesions in
patients with significant medical comorbid conditions, such
as coronary artery disease requiring angioplasty or bypass
grafting that has not or cannot be revascularized, history of
congestive heart failure, current ejection fraction 30% or
less, steroid-dependent chronic obstructive pulmonary dis-
ease, or measured 1-second forced expiratory volume 30%
or less; primary lesions anatomically inaccessible at surgery;
and primary lesions with previous ipsilateral cervical radia-
tion therapy.
Clinical protocol and follow-up. Patients were re-
ferred to the program after findings at history, physical
examination, and duplex ultrasound (US) scanning con-
firmed eligibility for participation. Clinical, angiographic,
and procedural data were prospectively collected. Angio-
graphic stenosis was determined with criteria of the North
Atlantic Symptomatic Carotid Endarterectomy Trial.11 In-
stent least luminal diameter was compared with the distal
nontapering portion of the internal carotid artery serving as
the reference segment. Postprocedure clinical examination
and duplex US scanning were performed before discharge,
to confirm stent patency and position and to establish a
baseline. Each patient was subsequently followed up with
serial and clinical evaluation at 6-month intervals. Techni-
cal failure was defined as inability to access or treat the
lesion, or residual stenosis 20% or greater after CAS. Pa-
tients were assessed for neurologic complications at each
visit, including amaurosis fugax (focal retinal deficit re-
solved in 4 hours), transient ischemic attack (TIA; focal
hemispheric deficit resolved in 24 hours), and stroke
(focal hemispheric deficit lasting 24 hours).
All duplex US scanning was performed at the same
Intersocietal Commission on Accreditation of Vascular
Laboratories (ICAVL)–approved vascular laboratory. Ve-
locity criteria used to identify individual categories of ste-
nosis have been validated in our laboratory and are based on
a modification of the University of Washington criteria12:
peak systolic velocity (PSV) less than 130 cm/s, 0% to 39%;
PSV 130 to 210 cm/s, 40% to 59%; PSV 210 to 300 cm/s
with end-diastolic velocity less than 120 cm/s, 60% to 79%;
PSV greater than 300 cm/s and end-diastolic velocity
greater than 120 cm/s, or internal carotid to common
carotid artery systolic velocity ratio greater than 3.2, 80% to
99%. Clinically significant recurrent stenosis was defined as
any ISR of 80% or greater. These recurrent stenostic lesions
were further evaluated with selective angiography, and
repeat intervention was performed when ISR was con-
firmed to be 80% or greater. Endovascular repeat interven-
tion was offered to all patients with ISR 80% or greater. The
procedure followed the same protocol as the primary inter-
vention. However, angioplasty alone was preferred, with
additional stenting performed if results were suboptimal
(residual in-stent recurrent stenosis 20%). Patients were
followed up at 3-month intervals for the first year, and every
6 months thereafter.
Carotid artery stenting protocol. The protocol used
for performing CAS has been described in detail by our
group.1,5,13 In brief, all patients received aspirin, 325 mg
once a day, and clopidogrel, 75 mg twice a day, for 2 days
before the procedure. The procedure was performed with
the patient under local anesthesia without sedation. Hepa-
rin was administered to achieve an activated clotting time of
250 to 300 seconds. Access was achieved through the
common femoral artery, and the left brachial artery in one
procedure. Digital angiography was performed to verify the
severity of stenosis. Intracerebral views were obtained to
establish baseline cerebrovascular anatomy. Self-expand-
able stents were used in all but four procedures, in which
short balloon-expandable stents were used early in our
experience. Stenoses were crossed with 0.018-inch Road-
runner extra-support guide wires (Cook Inc, Bloomington,
Ind) for the WallStents (Meditech/Boston Scientific, Min-
neapolis, Minn), and 0.014-inch guide wires (Hi-Torque
Floppy; Guidant, Menlo Park, Calif) for the Acculink ca-
rotid stents (Guidant). An antiembolic filter device (Accu-
net; Guidant) was used in all cases in which the Acculink
stent was delivered. On completion, ipsilateral cervical and
intracranial carotid angiography was performed to assess
technical success and to exclude distal cerebral emboliza-
tion. Post-procedure, patients were monitored in an inter-
mediate care facility overnight, and were discharged the
next morning. Clopidogrel was continued for 4 weeks, and
aspirin indefinitely.
Statistical analysis. Data are expressed as mean SD.
Thirty-day stroke and death rates and minor neurologic
complication rates after CAS in patients with post-CEA
recurrent stenosis versus primary lesions were compared
with the Fisher exact test. Time to ISR was analyzed with
life-table methods and Kaplan-Meier curves. Differences in
ISR rates between symptomatic versus asymptomatic le-
sions, post-CEA recurrent stenosis versus primary lesions,
and WallStents versus Acculink stents were assessed with
log-rank statistics.
RESULTS
Patient characteristics. Carotid artery stenting proce-
dures (n  122) were performed in 118 patients between
September 1996 and March 2003 in a dedicated endovas-
cular suite. Fifty-five percent of patients had asymptomatic
stenosis; 45% had symptomatic lesions. Indications for ca-
rotid artery stenting included recurrent stenosis after pre-
vious CEA (66%), primary lesions in high-risk patients
(29%), and previous ipsilateral cervical radiation therapy
(5%). Clinical characteristics are presented in Table I.
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Thirty-day outcome of carotid artery stenting. The
lesion was accessed and the procedure performed success-
fully in all cases, for a technical success rate of 100%. Mean
stenosis treated was 86%  8%, and post-treatment mean
residual stenosis was 9% 4%. WallStents were deployed in
72 procedures (59%), Acculink stents in 46 procedures
(38%), and balloon-expandable stents in 4 procedures (3%)
early in our experience. All Acculink stent deployments
were performed with an antiembolic device (Accunet). No
subintimal dissection, contrast material extravasation, arte-
rial disruption, or conversion to open surgery were encoun-
tered. Overall 30-day stroke and death rate was 3.3%, and
included one retinal infarction, one hemispheric stroke, and
two deaths. One death occurred from a myocardial infarc-
tion 10 days after discharge, and the other from an intra-
cranial hemorrhage. Minor neurologic events were noted in
7 patients, including TIA in 6 patients and amaurosis fugax
in 1 patient, for a minor neurologic complication rate of
5.7%. Post-event computed tomography (CT) scans dem-
onstrated no acute stroke, and duplex US scans demon-
strated no carotid dissections or thromboses in patients
with minor neurologic events. There were no significant
differences between patients treated for post-CEA recur-
rent stenosis versus primary lesions in the 30-day stroke and
death rates (n  2 each; P  .61), incidence of minor
neurologic events (n 3 and n 4, respectively; P .23),
or a combination of both (P  .19). Mean in-hospital
length of stay was 1.7  1 day.
Long-term follow-up. Over follow-up of 1 to 74
months (mean, 18.8  10 months), 22 patients demon-
strated ISR 40% or greater. None of these 22 patients had
symptoms at presentation, and ISR was diagnosed at du-
plex US scanning during routine follow-up. Although re-
current stenotic lesions ranged from 40% to 99%, only 5
patients demonstrated clinically significant ISR (80%); of
the remaining patients, ISR was 40% to 59% in 11 patients
and 60% to 79% in 6 patients. The distribution of various
ranges of ISR in the cohort at the end of follow-up are
shown in Fig 1. Most recurrent stenosis 40% or greater
occurred within 18 months of intervention (13 of 22, 60%),
and most clinically significant recurrent stenosis 80% or
greater occurred within 15 months (3 of 5, 60%; Fig 2).
On the basis of serial duplex US scans obtained after
122 procedures, 22 arteries had evidence of recurrent ste-
nosis at the date of last follow-up; stenosis was clinically
insignificant in 17 of these arteries, and clinically significant
in 5, yielding absolute recurrence rates of 18.0%, 13.9%,
and 4.1%, respectively (Fig 1). However, with cumulative




Age (y) (mean  SD) 70  9
Female gender 52 43
Type of lesion
Asymptomatic carotid stenosis 67 55
Symptomatic carotid stenosis 55 45
Amaurosis fugax 4 3
Transient ischemic attack 27 22
Stroke 24 20
Severity of stenosis (%) (mean  SD) 86  8
Indication for carotid artery stenting
Post-CEA recurrent stenosis 80 66
Previous ipsilateral cervical radiation 6 5
CAD that has not or cannot be revascularized 30 25
CHF or EF  30% 8 7








Current or past smoker 45 37
CEA, Carotid endarterectomy; CAD, coronary artery disease; CHF, conges-
tive heart failure; EF, left ventricular ejection fraction; COPD, chronic
obstructive pulmonary disease; FEV, forced exhaled volume in 1 second.
Fig 1. Distribution of various ranges of in-stent recurrent stenosis
in the cohort at end of follow-up.
Fig 2. Time to development of in-stent recurrent stenosis. Most
recurrent stenosis 40% or greater occurred within 18 months of
intervention (13 of 22, 60%), and most clinically significant recur-
rent stenosis 80% or greater occurred within 15 months (3 of 5,
60%).
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life table analysis, projected recurrence rates for 1 and 5
years were 2.7% and 6.4%, respectively, for clinically signif-
icant disease (in-stent recurrent stenosis 80%; Fig 3, A;
Table II, online only). Cumulative rates of in-stent recur-
rent stenosis 60% or greater at 1 and 4 years were 6.2% and
16.4%, respectively (Fig 3, B; Table III, online only), and of
in-stent recurrent stenosis 40% or greater were 9.0% and
42.7%, respectively (Fig 3, C; Table IV, online only).
Standard error was 10 or less for all results reported.
Log-rank statistics demonstrated no significant differ-
ences at 42 months in cumulative ISR (40%)–free rates
between WallStents and Acculink stents (68.1% vs 72.3%;
P  .77), presence or absence of preoperative neurologic
symptoms (66.6% vs 75.9%; P .67), and recurrent steno-
sis or primary carotid stenosis (71.8% vs 77.2%; P  .93).
Similarly, log-rank statistics in this small cohort demon-
strated that ISR rates were no different between male versus
female patients, smokers versus nonsmokers, and patients
with or without diabetes.
Management of in-stent restenosis. Patients with
moderate ISR (40%-79%) were followed up with serial
clinical evaluation and duplex US scanning at 3-month to
6-month intervals. The 5 patients with hemodynamically
significant ISR (80%) underwent diagnostic angiography,
which confirmed 80% or greater reduction in lesion diam-
eter. Recurrences were located within or at the proximal or
distal edge of the stent in all 5 instances. Patients were
preferentially offered endovascular repeat intervention.
Four lesions were successfully treated with repeat angio-
plasty, whereas one demonstrated a suboptimal response. A
Palmaz stent (Cordis, Miami Lakes, Fla) was placed across
this lesion to obtain a satisfactory result (20% residual
ISR). During follow-up 1 year later this patient had asymp-
tomatic internal carotid artery occlusion. Three patients
who underwent angioplasty alone have remained recur-
rence-free. One patient required two additional balloon
angioplasty procedures over follow-up of 3 years, and is
currently symptom-free, with duplex US scan–confirmed
ISR of 40% to 59% that has been stable for 13 months.
None of the patients have undergone surgical stent removal
since initiation of our program in 1996.
DISCUSSION
The long-term outcome after CEA has been well-
documented in several studies14,15; however, despite sev-
eral thousand CAS procedures reported in the literature,8
the long-term incidence of ISR remains ill-defined. In
addition, the high incidence of recurrent stenosis after
coronary stenting16 and iliac angioplasty with stenting17
has prompted several clinicians to question the durability of
the CAS procedure. In-stent recurrent stenosis after carotid
artery stenting has been reported as a relatively infrequent
complication by some authors. Wholey et al8 reported a
rate of only 3.5%, Diethrich et al18 defined a recurrent
stenosis rate of 4.5%, Yadav et al9 reported 4.9%, and
Theron reported 4%.10 In a previous report, we noted an
incidence of 8%.5 However, all of these reports were based
on short follow-up.
With longer follow-up, and now with the use of life
table analysis, we are able to report more informative data
on ISR after carotid artery stenting. The life table method
represents recurrences reported relative to the patient pop-
ulation at risk during a given interval of observation. These
data therefore demonstrate all accumulated information
Fig 3. Cumulative life table analysis. A, Projected recurrence rates
for 1 and 5 years were 2.7% and 6.4%, respectively, for clinically
significant disease (in-stent recurrent stenosis 80%. Cumulative
rates of in-stent recurrent stenosis 60% or greater at 1 and 4 years
were 6.2% and 16.4%, respectively (B), and of in-stent recurrent
stenosis 40% or greater were 9.0% and 42.7%, respectively (C).
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 6 Lal et al 1165
weighting the data in relationship to the duration of follow-
up. Emphasis is placed on data at 60-month follow-up,
when the incidence of arteries free of 80% or greater in-
stent recurrent stenosis was 6.4% (Fig 3). Therefore the
incidence of hemodynamically significant ISR is higher
than the figures published in the literature, which were
based on the short-term studies quoted above.
In addition, we demonstrate development of moderate
degrees of ISR in several patients from this cohort. The
incidence of ISR 40% or greater and 60% or greater was
42.7% and 16.4%, respectively, at 48-month follow-up.
Our previously reported data on CEA (Fig 4) noted a life
table incidence of recurrent stenosis 50% or greater to be
19% at 48 months.14 Similar data regarding durability of
CEA have been published by other groups.15 Admittedly,
historical data for CEA using duplex US scanning criteria
for greater than 50% stenosis are not directly comparable
with the current CAS follow-up data in which ICAVL-
approved duplex US scanning criteria for stenosis 40% or
greater and 60% or greater were used. However, it is clear
that in a significant number of patients moderate in-stent
recurrent stenosis will develop after carotid artery stenting,
some of which will progress to high-grade stenosis. Infor-
mation regarding this subgroup of moderate stenosis has
not been emphasized in the literature. These data show the
importance of life table assessment, and demonstrate that
ISR is an on-going process that requires long-term follow-
up. Our mean follow-up of 18.8 months (range, 1-74
months) is significantly longer than previously reported in
the literature, and our current analysis enables a more
realistic appraisal of ISR across ranges of 40% to 59%, 60%
to 79%, and 80% to 99%. Our data provide reassurance that
on life table analysis hemodynamically significant (80%)
ISR after CAS was 6.4% at 5 years. While encouraging, this
observation must be confirmed with a randomized compar-
ison of the two procedures, such as is being conducted
under the auspices of the National Institutes of Health
(Carotid Revascularization and Endarterectomy vs Stent
Trial [CREST]).19 At our institution we have not used
angiography to evaluate asymptomatic stenosis less than
80% by our ICAVL-approved vascular laboratory. There-
fore patients with in-stent recurrent stenosis less than 80%
did not undergo angiography. On the basis of these obser-
vations, we recommend close and frequent long-term du-
plex US scanning of all patients undergoing carotid artery
stenting. Our own protocol includes clinical examination
and duplex US scanning at 6-month intervals.
Of interest, ISR after carotid artery stenting was not
associated with neurologic events. Recurrent stenosis after
CEA also was associated with low rates of neurologic
symptoms in several studies.14,15 The absence of significant
neurologic complications indicates that these are primarily
myointimal hyperplastic lesions. While our analysis demon-
strates that most of these lesions occur within the first 36
months of follow-up (Fig 2), some recurrent stenoses have
been documented after longer follow-up and suggest the
possibility of recurrent atherosclerotic plaque as a possible
cause. In the absence of pathologic material, this assump-
tion of myointimal hyperplasia occurring in the first 36
months, and atherosclerotic plaque thereafter, is based on
previous reports.20
Patients with hemodynamically significant in-stent re-
current stenosis were treated successfully with further en-
dovascular interventions, namely, angioplasty alone or in
combination with stenting. Four of five lesions responded
well to angioplasty alone, whereas one lesion required an
additional stent. Embolic neurologic complications have
been reported in some instances after endovascular treat-
ment of ISR.21 No periprocedural complications were
noted in our series; however, one patient did have asymp-
tomatic occlusion after 1 year. Surgical removal of a stent
has not been required in this series; however, anecdotal
reports in the literature suggest that this and other surgical
procedures may be required in rare instances.22,23 One
Fig 4. Life table incidence of recurrent stenosis 50% or greater was 19% at 48 months.
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patient has required three balloon dilations to maintain
arterial patency over 3 years. Notwithstanding the recom-
mendations for conservative management of these asymp-
tomatic lesions by some groups,24 we suggest management
of these high-grade stenoses with catheter-based tech-
niques to prevent occlusion of the artery and possible
neurologic complications.
There has been some speculation that CAS of recurrent
stenotic lesions may be associated with higher rates of ISR
secondary to stimulation of an already activated intimal
hyperplastic lesion. In addition, stent material and physical
properties have been hypothesized to influence recurrence
rates.16 The correlation of the degree of stent-induced
injury to the vessel wall, with the extent of intimal hyper-
plasia, has been shown in experimental models.16 Log-rank
analysis of Kaplan-Meier curves for symptomatic versus
asymptomatic lesions in this series did not demonstrate any
significant differences in proportion of recurrence-free ar-
teries. Similarly, there were no differences in recurrence-
free survival observed between patients who received Wall-
Stents versus Acculink stents, both of which are self-
expanding stents. Balloon-mounted stents were deployed
in too few instances in this series to compare them with
self-expanding stents. No difference was noted in the pro-
portion of recurrence-free arteries between patients treated
for recurrent stenotic disease after CEA versus primary
atherosclerosis. These results must be interpreted with cau-
tion, because a larger cohort may be required to unmask
minor differences in long-term durability. Of interest, two
separate industry- sponsored trials using two different
stents (Acculink and Precise) have reported similar short-
term complication rates of 30-day stroke, death, or myo-
cardial infarction for both (7.8 vs 5.8%, respectively)4
(M.H. Wholey, 2003, personal communication). Data for
follow-up longer than 6 months and ISR rates are not
available.
The ultimate value of CAS compared with CEA will be
based on randomized clinical trials in North America
(CREST19) and Europe (Stent-protected Percutaneous
Angioplasty of the Carotid vs Endarterectomy
[SPACE]25). Within the next 2 to 3 years data will be
available on the efficacy of these two procedures in treating
primary extracranial carotid occlusive disease. Our study,
comprising 66% post-CEA restenosis lesions, indicates that
at long-term follow-up with life table analysis, the incidence
of ISR after CAS is higher than that reported in the litera-
ture. We also demonstrate development of moderate de-
grees of ISR (40%-79%) in a significant number of patients.
Both types of lesions tend to occur early in the course of
follow-up, and may not be associated with neurologic
complications. These findings suggest continuing use of
carotid artery stenting under careful institutional review
board supervision or in well-designed, well-controlled ran-
domized studies in selected patients at high-risk.3 They also
emphasize the importance of regular duplex US scanning
and clinical follow-up to monitor long-term complications.
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DISCUSSION
Dr Daniel Clair (New York, NY). I’d like to congratulate Dr
Lal on an excellent presentation and the authors on a well-written
paper addressing a topic that I believe most surgeons think has
receive limited attention by nonsurgeons performing this proce-
dure. I’d also like to thank the authors for supplying me with a copy
of their manuscript for review.
I have several questions for the authors regarding their study.
In terms of classification of the lesions, degree of stenosis with
duplex ultrasound, are there any changes in specific duplex criteria
that were utilized in patients evaluated with ultrasound in the
poststenting situation?
It is clear that data generated from duplex evaluations have
been confirmed in patients with primary carotid stenosis; however,
the stents clearly alter the hemodynamics of the bifurcation and
may affect classification of duplex ultrasound data in terms of the
degree of stenosis. Were there any other evaluations done of these
patients to confirm the degree of stenosis on the poststenting
duplex evaluations?
Another question I have relates to standard errors (SEs) that
were missing from the life table analysis at the 60-month time
point. It was difficult with a mean follow-up of 18 months to get a
sense of how meaningful the data at 60 months would be for this
patient population without some form of SE bars on the life table
analysis graphs.
Another question I have relates to information gained from
this study in terms of the technique of carotid artery stenting.
There are a limited number of patients who went on to have
reintervention, and I’m sure those patients have had review of their
initial angiographic data. Since the occurrences usually occurred at
the stent end points, were there any abnormalities at the stent end
points at initial stent placement? Specifically, were there problems
with the stent-to-arterial wall coapctation in these regions, in-
creased tortuosity, especially at the distal end points, or any other
issues which may have altered the authors’ techniques of carotid
stenting in these patients?
Dr Brajesh K. Lal. In terms of changes in duplex ultrasound
diagnostic criteria, the patients were scanned using the same crite-
ria in our ICAVAL-approved laboratory. We have noticed changes
in velocities in some of our patients and, in fact, are going to report
a detailed analysis of this at the upcoming national meeting (Vas-
cular 2003). We are revising our velocity criteria; however, our
follow-up protocol also incorporates detailed B-mode scans in any
patient identified as having restenosis on the basis of velocity
criteria. Only then is the patient categorized as having a significant
in-stent restenosis.
All the graphs clearly indicate the standard errors at the
bottom. All the data reported at 60 months for 80% in-stent
restenosis and at 48 months for the 60% and 40% in-stent resteno-
ses are with standard errors less than 10. So they’re all significant in
that respect.
As far as the technique for reintervention is concerned, I agree
with you: little has been written about it because very few of the
physicians who have published on carotid stenting in large num-
bers have analyzed their incidence of in-stent restenosis, using life
table analysis.
We chose to report our in-stent restenoses and discuss the
technique and approach that we have used to try and open up a
discussion on this fact. One of our patients, as we have described,
went on to occlude after restenting. Another required 3 subse-
quent interventions to maintain arterial patency and is currently at
40% to 59% in-stent restenosis. So when do we call a halt and
operate on these patients? These are issue that still need to be
studied, reported, and debated.
Dr Ali F. AbuRahma (Charleston, WV). I’d like to empha-
size a point, which I hope the author includes in the paper prior to
submitting it to the Journal of Vascular Surgery, since the study
will be quoted by many of our nonsurgical colleagues in North
America. As the author indicated, a significant number of his
patients have stenoses of80%; as a matter of fact, you have a total
of 14 patients with stenoses of 40% to 60% and 60% to 80% in this
group. Can you imagine if the follow-up were longer? Some of
these patients could have progressed to80%. Therefore, perhaps
the paper should emphasize the fact that even though the numbers
of patients with stenoses of80% was somewhat low at 18 months,
this number could increase if the follow-up was longer.
Dr Lal. We agree on the importance of long-term follow-up.
We have emphasized that there are several patients with in-stent
restenosis who have not approached the hemodynamically signifi-
cant (80%) limit That is why this study incorporated reporting on
the 60% and the 40% in-stent restenosis rates. These patients do
require longer follow-up and there’s more to the story that may
evolve later. Most of the publications on in-stent restenosis after
CAS are on short-term follow-ups, with reporting of 80% resteno-
sis. The current study identifies the entire range of restenoses.
Dr Bruce Perler (Baltimore, Md). My question relates to the
obvious dramatic improvement in outcome in your center. As I
recall Dr Hobson’s earlier report, which you cited, at 1 year the rate
of 80% restenosis was 8%. And now you’re telling us that at 5
years the rate of 80% restenosis is about 6.5%. So I wonder whether
that initial cohort of 50 patients was included in this series of 100
cases. And whether it was or wasn’t, might you speculate on why
the long-term durability has gotten so much better? I could see
periprocedural morbidity improving with experience, but I’m not
sure I understand why the durability would improve. Is there a
change in your selection of stent, change in technique, or some
other cause?
I ask because, as the other speakers have said, there clearly are
other series reporting much more dramatic rates of restenosis, such
as CAVATAS, where at 1 year a severe restenosis or occlusion
occurred in, I believe, 23% of patients, and other series support
that. So why are your results becoming so much more durable?
How have you changed what you’re doing?
Dr Lal. To answer your last question first, in CAVATAS the
majority of patients were treated with angioplasty alone, and
carotid stenting was a rescue procedure that occurred in only 25%
of the patients. That may explain the high restenosis rates in that
study. After the four restenoses noted in our first 50 patients, there
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